AVBPHealthcare · BiotechnologyThe 11 Wall Street analysts covering Arrivent BioPharma, Inc. hold a median 12-month price target of $18 — +7.2% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 33 of 100 as at 14 Oct 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.
Consensus tells you what everyone already believes. The model scores Arrivent BioPharma, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Value (67): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.
Revisions (29): Analysts have, on balance, been cutting their forecasts.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on AVBP, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +7.2% from it.
Of the 20 most recent actions, 2 moved their price target up and 7 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 8 Oct 2026 | HC Wainwright & Co. | Maintains | Buy | $47 → $27 |
| 7 Oct 2026 | BTIG | Maintains | Buy | $42 → $29 |
| 7 Oct 2026 | Citigroup | Maintains | Buy | $40 → $20 |
| 7 Oct 2026 | Guggenheim | Maintains | Buy | $45 → $18 |
| 7 Oct 2026 | Jones Trading | Maintains | Buy | $45 → $22 |
| 7 Oct 2026 | Truist Securities | Maintains | Buy | $45 → $18 |
| 17 Aug 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 17 Aug 2026 | HC Wainwright & Co. | Maintains | Buy | $44 → $47 |
| 13 Aug 2026 | BTIG | Reiterates | Buy | — |
| 13 Aug 2026 | BTIG | Reiterates | Buy | $42 |
| 13 Aug 2026 | Citigroup | Maintains | Buy | — |
| 13 Aug 2026 | Citigroup | Maintains | Buy | $43 → $40 |
| 13 Aug 2026 | Guggenheim | Reiterates | Buy | $45 |
| 13 Aug 2026 | Guggenheim | Reiterates | Buy | — |
| 29 May 2026 | Truist Securities | Maintains | Buy | — |
| 29 May 2026 | Truist Securities | Maintains | Buy | $43 → $45 |
| 13 May 2026 | Citigroup | Maintains | Buy | — |
| 24 Apr 2026 | Citigroup | Maintains | Buy | — |
| 23 Mar 2026 | B. Riley Securities | Maintains | Buy | — |
| 12 Mar 2026 | BTIG | Assumes | Buy | $42 |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. AVBP appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 15 Oct 2026, Arrivent BioPharma, Inc. returned −18.4% against +16.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 89% of US stocks
Cheaper than 41% of US stocks
Cheaper than 74% of US stocks
Higher than 32% of US stocks
Higher than 30% of US stocks
Higher than 21% of US stocks
Higher than 12% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Arrivent BioPharma, Inc. has a market value of $827.6M and an enterprise value of $426.0M.
Revenue in the twelve months to 30 June 2026: $0.0.
Net income over the same four quarters: −$163.7M.
Free cash flow in the twelve months to 30 June 2026: −$147.9M.
Trailing P/E: −3.9×; forward P/E: −4.3× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Arrivent BioPharma, Inc. employs 77 people.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Arrivent BioPharma, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
ArriVent BioPharma shares lost more than half their value after the pivotal Phase 3 FURVENT trial of its lead candidate firmonertinib missed its primary endpoint. An investigation into potential securities law violations is underway on behalf of AVBP investors.
Why it matters — The trial result and investor-focused investigation are material developments for those following AVBP.
ArriVent BioPharma announced that the first patient in the U.S. Phase 1 trial of ARR-002 has been dosed. ARR-002 is a potential first-in-class tetravalent MUC16/NaPi2b dual-target ADC being developed for ovarian and endometrial cancer.
Why it matters — The first dose marks the start of clinical evaluation for AVBP’s ARR-002 program.
Business Wire reported that SBS Law is offering AVBP investors with $100,000 in losses an opportunity to join a fraud investigation involving ArriVent BioPharma, Inc.
Why it matters — AVBP watchers may note the reported investigation and the invitation to affected investors.
ArriVent BioPharma said its Phase 3 FURVENT trial of firmonertinib failed to meet its primary endpoint. The notice says AVBP shares fell 56.7% in premarket trading on October 6, 2026, and were near a $12.09 52-week low.
Why it matters — AVBP watchers may be concerned about the trial result and the reported share-price decline, alongside the company’s recent $250 million at-the-market stock offering.
ArriVent BioPharma shares fell Tuesday, with trading volume of 14.10 million compared with an average of 524,163, according to Benzinga Pro. The headline reports that its lung cancer drug failed the primary trial endpoint and the stock reached a 52-week low.
Why it matters — The reported trial result and unusually high trading volume are relevant developments for investors following AVBP.
The 11 Wall Street analysts covering Arrivent BioPharma, Inc. have a median 12-month price target of $18, with estimates ranging from $15 to $29. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 11 analysts covering Arrivent BioPharma, Inc., 11 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Arrivent BioPharma, Inc. 33 out of 100 across roughly 4,600 US stocks as at 14 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 14 Oct 2026, Arrivent BioPharma, Inc. ranks 33 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (67 of 100).
No one can know that. What the data says: the median 12-month target from 11 analysts implies +7.2% from the last close, and Ticker Nerd's factor model ranks Arrivent BioPharma, Inc. 33 out of 100 as at 14 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Arrivent BioPharma, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for AVBP are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $15 to $29 over the next 12 months.
Arrivent BioPharma, Inc. returned -18.4% over the 12 months to 15 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
ArriVent BioPharma, Inc. is a clinical-stage biopharmaceutical company focused on identifying, developing, and commercializing differentiated medicines for patients with difficult-to-treat cancers.
The most recent item we track (PRNewsWire, 13 Oct 2026): "ArriVent BioPharma (AVBP) Securities Investigation Notice - Levi & Korsinsky". ArriVent BioPharma shares lost more than half their value after the pivotal Phase 3 FURVENT trial of its lead candidate firmonertinib missed its primary endpoint. An investigation into potential securities law violations is underway on behalf of AVBP investors.
ArriVent BioPharma, Inc. is a clinical-stage biopharmaceutical company focused on identifying, developing, and commercializing differentiated medicines for patients with difficult-to-treat cancers. ArriVent BioPharma, Inc. concentrates on targeted oncology programs designed to address unmet medical needs, with particular emphasis on non-small-cell lung cancer and other solid tumors. Its current portfolio includes development of furmonertinib, an epidermal growth factor receptor mutant-selective therapy being evaluated across multiple EGFR mutation settings, as well as emerging pipeline candidates such as antibody-drug conjugates and other novel therapeutics. The company works through collaborations and in-licensing approaches to advance medicines from discovery into clinical development and, ultimately, patient access. Headquartered in Newtown Square, Pennsylvania, ArriVent BioPharma, Inc. plays a specialized role in the oncology biopharmaceutical market by focusing on precision therapies for genetically defined cancer populations.
CEO Dr. Zhengbin Yao Ph.D. · 77 employees · United States · https://arrivent.com
